<SEC-DOCUMENT>0000950170-21-003506.txt : 20211108
<SEC-HEADER>0000950170-21-003506.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108171117
ACCESSION NUMBER:		0000950170-21-003506
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		211388870

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-20211108.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2021-11-08T16:44:25.5643+00:00 --><!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:rcus="http://arcusbio.com/20211108">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_f3c39afd-c373-440e-b983-d6e0ae2f3b69" name="dei:EntityCentralIndexKey" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8">0001724521</ix:nonNumeric><ix:nonNumeric id="F_3675fa34-b47f-4086-ab30-1cdb0d2f2ef2" name="dei:AmendmentFlag" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rcus-20211108.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_bf281cdc-d454-4dfa-9873-7231852235c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-08</xbrli:startDate><xbrli:endDate>2021-11-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d8b52a8-ecbe-442f-8899-146101c5e153" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2c16620-be37-41e7-8c4f-1d74fcd862bb" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">November 08, 2021</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f43349e3-6a82-4f02-bd26-a8fc7700578f" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">Arcus Biosciences, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce628c74-57ca-432f-a727-b8cae31315a4" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed5c88cd-fdd9-486b-9ba0-4c5af3465bff" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-38419</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cb6bd93-3863-4555-8808-da1fdf23bf89" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">47-3898435</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68f512d0-c940-407d-88e9-81165778e2a9" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3928 Point Eden Way</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9be6514-170e-4232-94a3-e4654103fa4c" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Hayward</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d603746c-edc1-48e2-b3d8-c0113e09c7ca" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7093db0e-2471-4127-8e07-229e9a0b4b51" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94545</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4073fbd-af0e-49f2-9824-b2cea38db52f" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(510)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8962bd3b-892f-4c85-80b9-be5448d16bbe" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">694-6200</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44683fae-3e49-4132-956b-68170be712b7" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f0b4493-9ed7-4e4e-a5ec-5d1f6e069e15" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_509af5d1-47c4-47b1-b6b1-f3bdbe2655be" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_153cd2fa-4b9e-4a27-bd6e-dba4a60901ac" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06e82370-8f4f-44c3-bafc-e89f7f8dfee9" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock, Par Value $0.0001 Per Share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bdb3059-fec5-47d5-8799-0de5ffea3b77" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RCUS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8cc1ce1-982b-466c-b862-8f4d3152bfb5" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_cfa46aeb-98ed-4166-bb29-a42fe321d73e" contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 8, 2021, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2021. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exchange Act</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.62%;"></td>
    <td style="width:2.519%;"></td>
    <td style="width:87.861%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:12.4pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rcus-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Press release dated November 8, 2021.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:12.4pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.556%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:3.583%;"></td>
    <td style="width:0.759%;"></td>
    <td style="width:37.944%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARCUS BIOSCIENCES, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: November 8, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Terry Rosen, Ph. D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Terry Rosen, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rcus-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img230044022_0.jpg" alt="img230044022_0.jpg" style="width:149px;height:52px;">&#160;</p>
  <p style="text-indent:-0.834%;padding-left:0.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Domvanalimab</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font>&#160;</p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer (NSCLC)</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">Gilead Sciences has initiated its opt-in review process for our anti-TIGIT program</font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">If the option is exercised and closed, Arcus would receive a $275 million opt-in payment, and the parties would share equally R&amp;D expenses related to the anti-TIGIT program </font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">A decision is expected prior to the end of 2021 </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">Updated data from ARC-8, a Phase 1 study of quemliclustat, our small molecule anti-CD73 inhibitor for pancreatic cancer, is planned for fall 2021</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;">Arcus ended the quarter with $743 million of cash and investments and funding through at least 2023</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">HAYWARD, Calif. &#x2013; (BUSINESS WIRE) &#x2013; November 8, 2021 &#x2013;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on the ARC-7 study of domvanalimab. Gilead Sciences has initiated its opt-in review process to potentially obtain rights to the Arcus anti-TIGIT program. If the option is exercised and closed, Gilead would obtain rights to both domvanalimab and AB308, a second and differentiated anti-TIGIT antibody in the Arcus portfolio. A decision is expected prior to the end of 2021.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">&#x201c;The initiation of Gilead&#x2019;s opt-in review process for our anti-TIGIT program is an important step towards our shared commitment to develop differentiated combination therapies for people with cancer,&#x201d; said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. &#x201c;We expect to continue our strong momentum of significant program advancement and milestone achievement starting with an update this fall from our Phase 1 study of quemliclustat, our first-in-class small molecule CD73 inhibitor, in development for pancreatic cancer, an area of enormous unmet need. Quemliclustat is a central component of our late-stage development strategy for 2022 and beyond.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Corporate &amp; Partnership Updates</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Gilead initiated the opt-in review process for our anti-TIGIT program. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">A decision is expected prior to the end of 2021.  If Gilead exercises its option, and subject to receipt of applicable anti-trust approvals:</font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Arcus would receive a $275 million opt-in payment, and the parties would co-develop and share equally the global development costs related to the anti-TIGIT program.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Gilead would obtain rights to both</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> domvanalimab, our Fc-silent anti-TIGIT antibody currently being evaluated in Phase 2 and Phase 3 studies, and AB308, our Fc-enabled anti-TIGIT antibody currently in a Phase 1 study in advanced malignancies.</font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">If approved, Arcus and Gilead would co-commercialize and equally share profits and losses to both anti-TIGIT antibodies in the United States. Gilead would receive exclusive rights outside the U.S., subject to any rights of Arcus&#x2019;s existing partners, and Gilead would pay to Arcus tiered royalties ranging from the high teens to low twenties. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Our collaboration partner Taiho initiated a Phase 1 platform study</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> evaluating zimberelimab (our anti-PD1 antibody) with Taiho&#x2019;s intra-portfolio combinations targeting oncology indications. The TARP (Taiho-Arcus Platform) study is currently enrolling. Further details can be found at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">https://clinicaltrials.gov</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> Trial Identifier: NCT04999761.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Zimberelimab was approved in China</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> as a second-line treatment for recurrent/refractory classical Hodgkin lymphoma (CHL); Gloria Biosciences holds all rights to zimberelimab in China and conducts its development of zimberelimab independent of Arcus&#x2019;s activities.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Anti-TIGIT program</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;font-style:italic;">Recent Highlights</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Arcus conducted a second interim analysis (IA2) for ARC-7, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">our</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">open-label randomized Phase 2 study evaluating the safety and efficacy of domvanalimab plus zimberelimab vs. zimberelimab alone vs. domvanalimab plus zimberelimab and etrumadenant (dual adenosine A2a/A2b receptor antagonist) as a first-line treatment for PD-L1 &#x2265; 50% and EGFR/ALK wild-type, metastatic NSCLC.  The study has a target total enrollment of 150 patients who are being randomized 1:1:1 across three study arms and treated until disease progression or loss of clinical benefit. The timing of this interim analysis was pre-specified in the protocol to occur when a certain number of patients were randomized and had at least two disease evaluations. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Summary of Efficacy Observations from IA2:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone. </font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Zimberelimab alone continued to demonstrate activity similar to that of other marketed anti-PD-1 antibodies in the setting. </font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">As expected with immunotherapy treatments, continued deepening of response and greater tumor shrinkage were observed in patients with longer follow-up in both domvanalimab-containing arms.  </font></div></div>
  <div style="margin-left:13.6%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Wingdings;display:inline-block;font-size:11.0pt;font-family:Wingdings;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0a7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Since the previous interim analysis, the doublet continued to show encouraging activity relative to the monotherapy, and the triplet continued to numerically outperform the doublet.   </font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">As of the data cut-off date for this interim analysis, data for progression-free survival (PFS) was immature but indicated that fewer events of progression or death had occurred in the domvanalimab-containing arms compared to zimberelimab alone. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Summary of Safety Observations from IA2:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">No unexpected safety signals were observed; the current safety profile for each molecule in the study appeared to be consistent with known and published immune checkpoint inhibitors in this setting. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Early safety data from this interim analysis showed a lower incidence of infusion reactions relative to published numbers from other anti-TIGIT plus anti-PD-(L)1 clinical studies. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Arcus initiated enrollment of five expansion cohorts in the Phase 1b portion of the ARC-12 study evaluating AB308 plus zimberelimab in advanced malignancies.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> This study is designed to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB308 plus zimberelimab in tumor types believed to be potentially responsive to anti-TIGIT antibodies.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;font-style:italic;">Upcoming anti-TIGIT Milestones:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-7 is expected to be fully enrolled by mid-2022, and we anticipate a data presentation later in 2022, which will include progression-free survival data. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-10, an ongoing registrational Phase 3 study in first-line, locally advanced or metastatic PD-L1&#x2265;50% NSCLC, continues to enroll and, if positive, is intended to support the potential approvals of both zimberelimab monotherapy and domvanalimab plus zimberelimab. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AstraZeneca and Arcus remain on track to initiate the PACIFIC-8 registrational Phase 3 study to evaluate domvanalimab plus durvalumab, an anti-PD-L1 antibody, in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care, by the end of 2021.   </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">We are planning several additional clinical studies of domvanalimab-based combinations, including two additional Phase 3 studies anticipated to start in mid-2022.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Quemliclustat (small molecule anti-CD73 inhibitor)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;font-style:italic;">Upcoming Milestones:</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">An update on ARC-8, our Phase I study of quemliclustat plus zimberelimab and gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), is planned for this fall. This update includes data on approximately 30 patients treated at the 100mg and 125mg dose of quemliclustat. </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">We expect the randomized portion of ARC-8 to complete enrollment by the end of this month. This 90-patient cohort is evaluating quemliclustat plus zimberelimab and gemcitabine/nab-paclitaxel vs. quemliclustat plus gemcitabine/nab-paclitaxel to determine whether zimberelimab adds clinical benefit to the combination.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">We anticipate landmark six-month PFS data from the randomized portion of ARC-8 in mid-2022. These results will inform the design of our planned Phase 3 study with the goal of starting this first registrational study for quemliclustat in 2022.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Etrumadenant (A2a/A2b adenosine receptor antagonist)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;font-style:italic;">Upcoming Milestones:</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-4, our randomized Phase 1b study in EGFR+ NSCLC: we expect initial randomized data, including overall response rates and PFS, to be presented in 1H22.  ARC-4 is evaluating etrumadenant plus zimberelimab and chemotherapy vs. zimberelimab plus chemotherapy in EGFRmut tyrosine kinase inhibitor (TKI)-relapsed and refractory NSCLC.</font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-6, our Phase 1b/2 platform study in metastatic castration-resistant prostate cancer: we anticipate initial results in 2022 from the randomized cohort that is evaluating docetaxel versus docetaxel plus etrumadenant and zimberelimab. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Discovery Programs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;font-style:italic;">Upcoming Milestones:</font></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AB308 (Fc-enabled anti-TIGIT antibody) poster presentation at the 2021 Society for Immunotherapy of Cancer&#x2019;s (SITC) Annual Meeting, November 10-14, 2021.</font></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-block;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Poster #258, Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(8,29,34,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-tumor Immunity Alone and in Combination with Other I-O Therapeutic Agents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AB521 (HIF-2&#x3b1; inhibitor): we expect to initiate Phase 1 clinical development in the fourth quarter of 2021. This first study is in healthy volunteers and is designed to expeditiously characterize the pharmacokinetic and safety profile of AB521 and to identify the starting dose for the planned Phase 1/1b study in oncology patients.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">Financial Results for the Third Quarter 2021</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&middot;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Cash, cash equivalents and investments </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">were $743.4 million</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">as of September 30, 2021, compared to $735.1 million as of December 31, 2020. The increase was primarily due to gross proceeds of $220.4 million received upon the closing of the private placement of common stock under the Amended and Restated Stock Purchase Agreement with Gilead in February 2021, partially offset by cash utilized for our operations. We expect cash, cash equivalents and marketable securities on-hand to be sufficient to fund operations at least through 2023.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&middot;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Revenues:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Collaboration and license revenues were $9.5 million for the three months ended September 30, 2021, compared to $64.5 million for the same period in 2020. In the three months ended September 30, 2021, we recognized $7.7 million in collaboration revenue related to Gilead&#x2019;s ongoing rights to access our research and development pipeline in accordance with the Gilead collaboration agreement, as well as $1.8 million related to the Taiho collaboration agreement. In the three months ended September 30, 2020, we recognized $55.1 million in revenue related to Gilead's license to zimberelimab and $7.7 million in collaboration revenue related to their access to our research and development pipeline, as well as $1.8 million related to the Taiho collaboration agreement. Collaboration and license revenues were $28.4 million for the nine months ended September 30, 2021, compared to $68.0 million for the same period in 2020.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&middot;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">R&amp;D Expenses:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> Research and development expenses were $71.3 million for the three months ended September 30, 2021, compared to $51.8 million for the same period in 2020. The increase was primarily driven by costs incurred to support our expanded clinical and development activities including increased compensation costs related to a larger employee base, increased clinical trial costs, and increased early-stage research costs. Approximately $4.9 million of the increase in compensation costs is related to non-cash stock-based compensation. The overall increase in research and development expenses is partially offset by a decrease in milestone expenses incurred. Research and development expenses were $206.4 million for the nine months ended September 30, 2021, compared to $110.6 million for the same period in 2020.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&middot;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">G&amp;A Expenses:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> General and administrative expenses were $16.3 million for the three months ended September 30, 2021, compared to $11.2 million for the same period in 2020.  The increase was driven by the increased complexity of supporting our expanding clinical pipeline and collaboration obligations, as well as compliance costs associated with our growth. Our growing employee base and 2021 stock awards drove an increase in employee compensation costs, including approximately $3.7 million of increased non-cash stock-based compensation. The overall increase was partially offset by decreases in legal, accounting and consulting expenses due to costs related to the transaction with </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;visibility:hidden;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Gilead and other corporate development activities incurred in 2020. General and administrative expenses were $49.0 million for the nine months ended September 30, 2021, compared to $29.6 million for the same period in 2020.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.4029166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Symbol;display:inline-block;font-size:11.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&middot;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Net Loss:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> Net loss was $78.0 million for the three months ended September 30, 2021, compared to  net income of $1.8 million for the same period in the prior year.  Net loss was $226.5 million for the nine months ended September 30, 2021, compared to $71.0 million for the same period in 2020.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Arcus Clinical Study Overview</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.386%;"></td>
    <td style="width:29.004%;"></td>
    <td style="width:29.952%;"></td>
    <td style="width:14.935%;"></td>
    <td style="width:14.724%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Trial Name</font></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Arms</font></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Setting</font></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Status</font></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">NCT No.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">etruma + zim + carbo/pem vs. zim + carbo/pem</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">TKI R/R EGFRmut NSCLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing Randomized Phase 1/2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT03846310</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">etruma + zim + SOC vs. SOC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">2L/3L CRPC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04381832</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">zim vs. zim + dom vs. zim + dom + etruma</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">1L NSCLC (PD-L1 &#x2265; 50%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04262856</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">1L PDAC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing Randomized Phase 1/1b</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04104672</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">etruma + zim + mFOLFOX vs. SOC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">2L/3L/3L+ CRC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04660812</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">&#160;chemo vs. zim mono vs. zim + dom</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">1L NSCLC (PD-L1 &#x2265; 50%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing Registrational</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04736173</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AB308 + zim</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Advanced Malignancies</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Ongoing</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Phase 1/1b</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">NCT04772989</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">ARC-14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">AB521</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Healthy Volunteer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Planned</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Phase 1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">NA</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">PACIFIC-8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">durva &plusmn; dom</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Curative-Intent Stage 3 NSCLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Planned Registrational</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">NA</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Carbo/pem: carboplatin/pemetrexed; dom: domvanalimab; durva: durvalumab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; quemli: quemliclustat; SOC: standard of care; zim: zimberelimab CRC: colorectal cancer; CRPC: castrate-resistant prostate cancer; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">About domvanalimab and AB308</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Domvanalimab, Arcus&#x2019;s most advanced anti-TIGIT candidate, is an Fc-silent investigational monoclonal antibody that binds to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response. Cancer cells can exploit TIGIT to avoid detection by the immune system. Domvanalimab binds to TIGIT to free up immune activating pathways and activate immune cells to attack and kill cancer cells.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Treatment with domvanalimab, an Fc-silent antibody, has not been associated with the depletion of peripheral regulatory T-cells. We believe this may result in fewer infusion reactions relative to what has been reported for other anti-TIGIT-containing regimens.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Arcus is developing a second anti-TIGIT candidate, AB308, an Fc-enabled investigational monoclonal antibody. AB308 is currently in a Phase I study for advanced malignancies.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">About the Gilead Collaboration</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">In May 2020, Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt in to all other Arcus programs arising during the collaboration term.  For clinical programs in existence at the date of the agreement, Gilead&#x2019;s opt-in payment ranges from $200 million to $275 million per program. For all other programs that enter clinical development thereafter, the opt-in payments are $150 million per program.  Gilead&#x2019;s option, on a program-by-program basis, expires after a prescribed period of time following the achievement of a development milestone for such program and Arcus&#x2019;s delivery to Gilead of the requisite qualifying data package.  Concurrent with the collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus. That stock purchase agreement was amended and restated in February 2021 in connection with Gilead&#x2019;s increased equity stake in Arcus from 13% to 19.5%, with an additional $220 million investment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">About Arcus Biosciences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences&#x2019; clinical and pre-clinical programs, please visit </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">www.arcusbio.com</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> or follow us on Twitter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein, including, but not limited to, statements regarding the potential exercise, timing and receipt of payments upon an exercise by Gilead of its option to our anti-TIGIT program, upcoming milestone  and associated timing for our programs, including those statements under the captions &#x201c;Upcoming Milestones&#x201d; above and expected enrolment in the studies and cohorts described herein, and our expectation that our cash, cash equivalents and marketable securities on-hand will be sufficient to fund operations through at least 2023, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability to obtain regulatory approval for any exercise by Gilead of its option; risks associated with preliminary and interim data; the unexpected emergence of adverse events or other undesirable side effects; the inherent uncertainty associated with the COVID-19 pandemic, including the duration and/or severity of the pandemic and actions by government authorities to contain or slow the spread of the virus; the inherent uncertainty associated with pharmaceutical product development and clinical trials; delays in our clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; our dependence on our collaboration with Gilead for the successful development and commercialization of our investigational products; and changes in the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3920833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">competitive landscape for our programs. Risks and uncertainties facing us are described more fully in our quarterly report on Form 10-Q for the quarter ended September 30, 2021 filed on November 8, 2021 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. We disclaim any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">The Arcus name and logo are trademarks of Arcus. All other trademarks belong to their respective owners.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">Source: Arcus Biosciences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">Investor and Media Inquiries:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"><br>Holli Kolkey<br>VP of Corporate Communications<br>(650) 922-1269<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Calibri;">hkolkey@arcusbio.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ARCUS BIOSCIENCES, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">(unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> (In thousands, except share and per share amounts)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.837%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:9.349%;"></td>
    <td style="width:0.908%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:9.228%;"></td>
    <td style="width:0.908%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:9.47%;"></td>
    <td style="width:0.908%;"></td>
    <td style="width:1.23%;"></td>
    <td style="width:1.493%;"></td>
    <td style="width:9.592%;"></td>
    <td style="width:0.908%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Revenues:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">License revenue</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,096</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,096</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,461</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,434</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">28,383</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,934</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total revenues</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,461</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">64,530</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">28,383</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,030</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">71,254</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">51,801</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">206,412</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">110,636</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">16,343</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11,177</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">48,990</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">29,617</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">87,597</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">62,978</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">255,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">140,253</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Income (loss) from operations</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(78,136</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,552</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(227,019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(72,223</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Non-operating income (expense):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest and other income, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">161</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">270</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">481</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,218</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gain on deemed sale from equity method investee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">613</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Share of loss from equity method investee</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(613</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total non-operating income, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">161</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">270</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">481</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,218</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(77,975</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,822</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(226,538</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(71,005</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other comprehensive income (loss)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(46</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(63</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(136</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Comprehensive loss</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(78,021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,759</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(226,674</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(70,988</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1.11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.03</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3.28</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1.37</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average number of shares used to<br>&#160;&#160;&#160;compute basic net income (loss) per share</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">70,110,138</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">62,599,193</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,990,290</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">51,852,247</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1.11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.03</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3.28</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1.37</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average number of shares used to<br>&#160;&#160;&#160;compute diluted net income (loss) per share</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">70,110,138</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">65,145,707</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,990,290</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">51,852,247</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Consolidated Balance Sheet Data</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">(unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> (In thousands)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.934%;"></td>
    <td style="width:1.724%;"></td>
    <td style="width:1.654%;"></td>
    <td style="width:12.828%;"></td>
    <td style="width:0.827%;"></td>
    <td style="width:1.724%;"></td>
    <td style="width:1.654%;"></td>
    <td style="width:12.828%;"></td>
    <td style="width:0.827%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and investments in marketable securities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">743,372</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">735,086</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">839,290</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">772,292</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296,683</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">269,988</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">542,607</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">502,304</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;">(1) Derived from the audited financial statements for the year ended December 31, 2020, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img230044022_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img230044022_0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z!#L# 2(  A$! Q$!_\0
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MKR#FCFCFCFO:,0YHYHYHYH _17_@E)\5MT7BSX<W<W*D:UIZL>QVQ3J/_()
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M%O,+<VV<#./XTR<!UXY .#Q7KE?,5*<J<G":LT="=]4%%%%9C"BBB@ HHHH
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MRC)QG&#V)KOZ_GL\/>)-5\(ZQ;:MHFHW6DZG;-OAN[.5HI8SZAE.:^T? _\
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MRJG_ '5%>W45\E7S#$XA^]*R[+0ZE",>A7L=/M=+MUM[.VAM+=?NQ01A%'T
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MO3AS:LT_#_A_3?">B66CZ-8P:;I=E$(;>TMD"1Q(.@ %:-%%?":O5G8%%%%
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MG460D$6L0WR#(Z%@ @/8N*_<BSLX-/M(+6UACMK:!%BBAA4*D:*,*J@<
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M'IN!\QNGWU!'R"OK&FHBQJJ(H55& JC  IU?F5>M+$5)59;L]&*Y59!1116
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M4 %%%% !1110 4444 %?D5_P4V_Y.>G_ .P1:?\ L]?KK7Y%?\%-O^3GI_\
ML$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0/#/\ V%+7_P!'+7]
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MV,H3'DR(JCYWVDJ=S+PB>E1?#G_@EY\,_"YCG\4:AJGC*Z4@M&[_ &.V./\
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M/_HIZ_;:OQ)_8H_Y.F^'7_80/_HIZ_;:OE\\_CQ]/U9T4?A"BBBOG#<****
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M&7FOLS_@J!\5_P#A+OC-I_@ZTFWV'A>TQ,JG@W<X5WZ=<1B$>QWBOC/FOO\
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M[J*X26&$JZ,CA@RX7J".*VCQO.I[KRZJK_X?\T92R>G%76)@_O/J>BBBLCS
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M"_[!OP.\*LKQ>!X-2F4Y\S5+F:YS]4=]G_CM>T^&_"&A>#K,6F@Z+I^B6O\
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M:^L/*&R1K-&R-G:P*G!P:_9?]CF[\-_%WX!^%O$,]DEYK$, T[4FGD+G[1
MC,1]T;U"R8QP)!UK\:N:^\_^"5/Q6_LOQAXF^'UY-B#58!JEBK'@3Q8655'J
MT95OI#7S6?9=0QV'4ZU-2=/572=K[VO\ON.W#8BK0DU3DXWWL['Z26>C6&G
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M[#MDQZQBO/Q]#ZQAY06^Z^1I"7+*Y^XM%-5ED565@RL,A@<@BG5^;G>%%%%
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M0*?%KX0Q>&-3N0_B;PJB6D@=OGGL\8@E'K@#RVZ\HI)^<5]85^#?P)^,VL?
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M+7] =?S]?#^01>/?#;M]U=3MB?PE6OZ!:^1S[XJ?S_0ZZ/4****^5.@****
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M444 %%%% !1110 45!>7EOI]K-=7<\=M;0J7DFF<(B*.26)X 'J:^)?VDO\
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M?5G>%%%% !7Y2?\ !4KPG_8_Q\TG6D7$6L:+$S-CK+%(\;?^.>57ZMU\$_\
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M:B_9UTK]I'X:W&A71CM-;M2UQI&I,.;:?&,,1SY;X"L.>QQE5K\4?%?A75?
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M[17XO:+^WU\==#C")XYDNT QMO;&VF/_ 'TT>[]:UYO^"CGQUD3:OB:RB/\
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M@AXJ_P# ^'_XQ1_PZU^#_P#T$/%7_@?#_P#&*/[9POG]P>RD?D[S1S7ZQ?\
M#K7X/_\ 00\5?^!\/_QBC_AUK\'_ /H(>*O_  /A_P#C%']LX7S^X/92/R=Y
MHYK]8O\ AUK\'_\ H(>*O_ ^'_XQ1_PZU^#_ /T$/%7_ ('P_P#QBC^V<+Y_
M<'LI'Y.\T<U^L7_#K7X/_P#00\5?^!\/_P 8H_X=:_!__H(>*O\ P/A_^,4?
MVSA?/[@]E(_)WFOWU^#W_)(_!'_8#L?_ $G2OFS_ (=:_!\_\Q'Q5_X'P?\
MQBOJ_P -Z#;>%_#NEZ+9M(UIIUK%9PM,VYRD:!%+'N< 9->'FF.I8N,%2OH;
M4X.-[GXB_M8?\G+?$O\ [#UU_P"C#7E'-?L!X\_X)T_"[XB>--;\4:I?^)$U
M'5[N2\N%M[V)8Q([;F"@PD@9/ )-8/\ PZU^#_\ T$/%7_@?#_\ &*]>EF^&
MA3C%WT2Z&3I2N?D[S1S7ZQ?\.M?@_P#]!#Q5_P"!\/\ \8H_X=:_!_\ Z"'B
MK_P/A_\ C%:_VSA?/[A>RD?D[S1S7ZQ?\.M?@_\ ]!#Q5_X'P_\ QBC_ (=:
M_!__ *"'BK_P/A_^,4?VSA?/[@]E(_)WFCFOUB_X=:_!_P#Z"'BK_P #X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&V?@G_P!#Y:_^ ES_ /&J /<**\T^'W[2'PW^*GB Z)X5\40:OJGDM/\
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M*** "BBB@ HHK!\;^.-#^''AF[\0>)-032]'M2@FNI$9@F]PB\*">68#@=Z
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M *635\+_ /!0[_DYK5_^O"S_ /10K[H_87_Y-7\#_P"Y=_\ I9-3 ]YHHHI
M%%%% &#X^_Y$3Q'_ -@VY_\ 135^'GA/PW<>,?%6C:!9R117>JWL-C#).2(U
M>6144L0"0 6&< \5^X?C[_D1/$?_ &#;G_T4U?B]\#?^2V?#_P#[&'3_ /TI
MCJD!]$_\.P_B7_T,/A7_ ,"+G_XQ1_P[#^)?_0P^%?\ P(N?_C%?IM12N!^9
M/_#L/XE_]##X5_\  BY_^,4?\.P_B7_T,/A7_P "+G_XQ7Z;447 ^,?V2_V+
M?&7P$^*S>)]=U;0[VQ.GS6GE:?+,TFYV0@X>)1CY3WK[.HHI %%%% !7(?&+
M_DD?C?\ [ =]_P"D[UU]<A\8O^21^-_^P'??^D[T ?AQS7VG_P $\OVDO^$3
MUY?AGX@NL:/JLV[2)I6XM[MCS#ST64]!_?[9<FOF[]G?2[/7/CEX&TW4;6&^
MT^\U:WMKBVN$#I+&[A64@^H)K:_:8^!>H?L\_%2ZTA3,VD3M]LT>_)P9("W
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M^A^T_P#[]S?_ !% 'M%%<SX ^)'AGXI:(^L>%=7AUK38YVMFN( P D4*2IW
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M]V.-,_4L?_9:[^&Z?M<VH1\[_<F_T./.9^SP%5^5OO:1[)1117]('XX%%%%
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M_10K[H_87_Y-7\#_ .Y=_P#I9-7PO_P4._Y.:U?_ *\+/_T4*^Z/V%_^35_
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M.^#KSX>_"OPIX9U"6">^TG38;.:2V),;.B $J2 2..X%=C10 4444@"BBB@
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MA[2*._\ $HW#^(+[_P#L?_MV6NCZ;9>"/B5>F*WMU6'3O$,N6"H.%BN#U '
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M_P#);/A__P!C#I__ *4QU^T/C[_D1/$?_8-N?_135^+OP-_Y+7\/O^QAT_\
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M,?\ P3S&@WUGXF^**6]W<Q$2V_AN-A)$C#D&X8?*^/\ GFN5]2PRM?=( 48
MP*6BI **** "BBB@#\GO^"AW/[36K\?\N%G_ .BA7W/^PO\ \FK^!^WR7?\
MZ635[K):PR-N>*-V]64$T](UC4*BA%'0*,"F ZBBBD 4444 8'C[_D1?$?\
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,%4 "KU( HHHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rcus-20211108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-11-08T16:44:25.7434+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://arcusbio.com/20211108" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:rcus="http://arcusbio.com/20211108" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20211108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20211108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rcus-20211108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-11-08T16:44:26.0069+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rcus-20211108.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>rcus-20211108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-11-08T16:44:25.8888+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>rcus-20211108_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20211108.xsd" xlink:type="simple"/>
    <context id="C_bf281cdc-d454-4dfa-9873-7231852235c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_f3c39afd-c373-440e-b983-d6e0ae2f3b69">0001724521</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_3675fa34-b47f-4086-ab30-1cdb0d2f2ef2">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_8d8b52a8-ecbe-442f-8899-146101c5e153">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_a2c16620-be37-41e7-8c4f-1d74fcd862bb">2021-11-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_f43349e3-6a82-4f02-bd26-a8fc7700578f">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_ce628c74-57ca-432f-a727-b8cae31315a4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_ed5c88cd-fdd9-486b-9ba0-4c5af3465bff">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_1cb6bd93-3863-4555-8808-da1fdf23bf89">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_68f512d0-c940-407d-88e9-81165778e2a9">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_d9be6514-170e-4232-94a3-e4654103fa4c">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_d603746c-edc1-48e2-b3d8-c0113e09c7ca">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_7093db0e-2471-4127-8e07-229e9a0b4b51">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_a4073fbd-af0e-49f2-9824-b2cea38db52f">(510)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_8962bd3b-892f-4c85-80b9-be5448d16bbe">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_44683fae-3e49-4132-956b-68170be712b7">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_3f0b4493-9ed7-4e4e-a5ec-5d1f6e069e15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_509af5d1-47c4-47b1-b6b1-f3bdbe2655be">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_153cd2fa-4b9e-4a27-bd6e-dba4a60901ac">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_06e82370-8f4f-44c3-bafc-e89f7f8dfee9">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_7bdb3059-fec5-47d5-8799-0de5ffea3b77">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_d8cc1ce1-982b-466c-b862-8f4d3152bfb5">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_bf281cdc-d454-4dfa-9873-7231852235c8"
      id="F_cfa46aeb-98ed-4166-bb29-a42fe321d73e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140122818195592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  08,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 9XEH4Y>*NQS     $P(
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
M" !GB6A399!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.
MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>
MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X
MJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/0
M8&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]
MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD
MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_
MYHOA/UY_ 5!+ 0(4 Q0    ( &>):%,'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 9XEH4^VT3)OM
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 9XEH4YE<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !GB6A32$7;1T$$  !,$
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 9XEH4Y^@&_"Q @  X@P   T              ( !@PP  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !GB6A3EXJ[',     3 @  "P
M        @ %?#P  7W)E;',O+G)E;'-02P$"% ,4    " !GB6A3.JJBYT !
M   \ @  #P              @ %($   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 9XEH4R0>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 9XEH4V60>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-20211108.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rcus-20211108.htm">rcus-20211108.htm</File>
    <File>rcus-20211108.xsd</File>
    <File>rcus-20211108_lab.xml</File>
    <File>rcus-20211108_pre.xml</File>
    <File>rcus-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rcus-20211108.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "rcus-20211108.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20211108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20211108_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rcus-20211108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20211108",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-20211108.htm",
      "contextRef": "C_bf281cdc-d454-4dfa-9873-7231852235c8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-20211108.htm",
      "contextRef": "C_bf281cdc-d454-4dfa-9873-7231852235c8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://arcusbio.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-21-003506-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-003506-xbrl.zip
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M6P:6G.U2N7RU_<I/DPZ7?::>_R<5WPL=XM:A_28)M>6U4B_,W=6!?S>A,MK
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MI>6'Y@M1[;L6EV?RR.7RPL/ROL,]=,\M9*!K9B,02P0DE#S 0H!\)" 329+
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MS@5/0CXD\3(\*Y[ROEY6\D<\X>K-\_P/6D%*)Y]^.FCU\T'\Z?\!4$L#!!0
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M@09.'Y>&%-&B%.='PF!!Q/@Z3)?"?*5%ETR[&DN5I=_]<7*']BK&A4[K2FK
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M_*!@BUT)";UM*?#:XL?5!W4&1_^1X>H_4$L#!!0    ( &>):%,'X=S5B@0
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MO)AJ/KI4PD^4P6L<C$$6LMR!E$H-[ZE"AD(F-X;$];HBQK5=G8RMT[U*%3"
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M_4K)8!K;-9]ZH='8<I?:&ZO)K)YZHZT9W;-P23Z[20:.\#2V /D-_.!$S=.
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MA<@_5]<F!(-(4Q "NN:;#@K#8+]OL :Q3:@BJER@_S%!.+C2Z7C!/-06X:+
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MK5+:K,8;TEPR.H]6ZV\WVEV$*=]D@T"QW7>-!6S^-UY(<WA8ZQUV'61NU?P
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MP#2_J;QLI+PL!AU5B;/'7>Z(L??5ZU9AR8Y64CE.67=49L,V%P]@S>8KU[;
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M,C R,3$Q,#@N:'1M4$L! A0#%     @ 9XEH4U>W>$,7 P  NPD  !$
M         ( !?1,  ')C=7,M,C R,3$Q,#@N>'-D4$L! A0#%     @ 9XEH
M4\GV0_2<!0  AS(  !4              ( !PQ8  ')C=7,M,C R,3$Q,#A?
M;&%B+GAM;%!+ 0(4 Q0    ( &>):%,'X=S5B@0  &XE   5
M  "  9(<  !R8W5S+3(P,C$Q,3 X7W!R92YX;6Q02P$"% ,4    " !GB6A3
M-*GY?;PV  #T. 0 #P              @ %/(0  <F-U<RUE>#DY7S$N:'1M
64$L%!@     %  4 00$  #A8      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
